Jylamvo (methotrexate) 2mg/ml oral solution
Jylamvo (methotrexate) 2mg/ml oral solution is for use in the following indications:
In rheumatological and dermatological diseases
- Active rheumatoid arthritis in adult patients.
- Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non steroidal anti inflammatory drugs (NSAIDs) has been inadequate.
- Severe, treatment refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.
- Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over
Arthritis is often associated with older people, but it can also affect children. In the UK, about 15,000 children and young people are affected by arthritis. Juvenile idiopathic arthritis (JIA) is inflammation (swelling) of one or more joints for at least 6 weeks.
Although the exact cause of JIA is unknown, the symptoms often improve as a child gets older.
In most cases children with JIA will be well controlled with treatment.
Signs and symptoms of JIA
Rheumatoid Arthritis (RA)
RA is a long-term condition that causes pain, swelling and stiffness in the joints. The symptoms usually affect the hands, feet and wrists. There may be periods where symptoms become worse, known as flare-ups or flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints.
Acute lymphoblastic leukaemia (ALL)
ALL is a rare type of cancer. It affects about 800 adults a year in the UK. ALL is most common in children and young people up to the age of 25, and in older adults over 75. It affects slightly more males than females.
ALL is a cancer of the white blood cells. Normally, white blood cells divide and grow in an orderly and controlled way. In leukaemia this process has gone out of control. Signals that stop the body making too many white blood cells are ignored. Therefore the cells go on dividing, but do not mature into normal lymphocytes. People with ALL make too many immature blood cells, called lymphoblasts (sometimes referred to as blasts). As the lymphoblasts do not mature, they can’t fight infection as normal white blood cells do. These immature cells fill up the bone marrow, which means there is not enough space to make all the healthy white cells, red cells and platelets your body needs.
Psoriasis is a common skin condition that speeds up the life cycle of skin cells. It causes cells to build up rapidly on the surface of the skin. The extra skin cells form scales and red patches that are itchy and sometimes painful. Psoriasis is a chronic disease that often comes and goes. The main goal of treatment is to stop the skin cells from growing so quickly.
While the exact cause of psoriasis isn't fully understood, scientists believe psoriasis is the result of several factors, including the immune system. When you have psoriasis, your immune system is overactive. This creates inflammation inside the body, which is a cause of the symptoms you see on the skin
Jylamvo (methotrexate) 2 mg/ml oral solution (SmPC - UK)
Jylamvo (methotrexate) 2 mg/ml oral solution (PIL - UK)
Jylamvo (methotrexate) 2 mg/ml oral solution (Educational Guide for Healthcare professionals - UK)
Jylamvo (methotrexate) 2 mg/ml oral solution (SmPC - Ireland)
Jylamvo (methotrexate) 2 mg/ml oral solution (PIL - Ireland)
Jylamvo (methotrexate) 2 mg/ml oral solution (Educational Guide for Healthcare professionals - Ireland)